Deals this week: ClearLight Diagnostics, Mitsubishi Tanabe Pharma Corporation, Samsung Biologics

6th October 2016 (Last Updated October 6th, 2016 18:30)

ClearLight Diagnostics and Oregon Health and Science University Centre for Spatial Systems Biomedicine (OCSSB) have entered a co-development agreement to analyse the tumour micro-environment and resistance associated interactions in pancreatic cancer patients, using 3D analysis.

ClearLight Diagnostics and Oregon Health and Science University Centre for Spatial Systems Biomedicine (OCSSB) have entered a co-development agreement to analyse the tumour micro-environment and resistance associated interactions in pancreatic cancer patients, using 3D analysis.

Under the agreement, ClearLight Diagnostics will be responsible for developing biomarkers to study the micro-environment of the pancreatic tumours by using its own tissue processing and 3D light sheet microscopy methods.

The agreement enables the two partners to spatially characterise the tumours and allows for the development of new therapies and diagnostics.

Mitsubishi Tanabe Pharma Corporation and Medicine for Malaria Venture (MMV) have entered a research agreement to develop a novel drug candidate for the treatment of malaria.

Under the agreement, the two partners have jointly studied and analysed three groups of compounds from the compound library that can potentially act against malaria.

The research will be performed with the support of Global Health Innovative Technology Fund (GHIT fund).

MMV’s screening partners Eskitis Institute, Griffiths University and University of California, San Diego (UCSD) have contributed to the high-throughput screening of the compounds.

Samsung Biologics plans to raise gross proceeds of up to $2 billion through the initial public offering (IPO) of 16.5m shares of its common stock.

Korea Investment & Securities, NH Investment Securities, Citigroup, JP Morgan Chase & Co and Credit Suisse Group AG are acting as the advisors for the offering.

The company plans to invest the funds to further develop its innovation technology, expand its presence in the biopharmaceutical market and repay its debts.

"ConvaTec plans to repay its existing debts through the funds raised from the IPO of its common stock shares."

ConvaTec plans to repay its existing debts through the funds raised from the IPO of its common stock shares.

The company expects to raise approximately $1.8 billion from the offering.

Carrick Therapeutics plans to expand its cancer therapies through the funds raised in a venture financing round.

The company has raised $95 million in the financing round led by ARCH Ventures partners and Woodford Investment Management, and co-led by Cambridge Enterprise Seed Funds, Cambridge Innovation Capital, Evotec AG, Google Ventures (GV), and Lightstone Ventures.


Image: Mitsubishi Tanabe Pharma Corporation and Medicine for Malaria Venture (MMV) have entered a research agreement. Photo: Courtesy of own work.